Tumor Site-Specific Cleavage Improves the Antitumor Efficacy of Antibody–Drug Conjugates
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241311011 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Keyuan Xu und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, Nankai University, Tianjin 300071, China. Hauptthemen laut MEDLINE: Immunoconjugates, Ovarian Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Key R&D Program of China, the National Natural Science Foundation of China, National Key R&D Program of China.
Abstract (Originalsprache)
Antibody—drug conjugates (ADCs) play important roles in tumor therapy. However, traditional ADCs are limited by the extremely large molecular weight of the antibody molecules, which results in low permeability into solid tumors. The use of small ADCs may be expected to alleviate this problem, but this switch brings the new limitation of a greatly shortened blood circulation half-life. Here, we propose a new cleavable ADC design with excellent tumor tissue permeability and a long circulation half-life by fusing the small ADC ZHER2-MMAE with the Fc domain of the antibody for circulation half-life extension, and inserting a digestion sequence between them to release the small ADC inside tumors for better tumor penetration. The experimental results showed that the designed molecule Fc-U-ZHER2-MMAE has a significantly increased blood circulation half-life (7.1 h, 59-fold longer) compared to the small ADC ZHER2-MMAE, and significantly improved drug accumulation ability at tumor sites compared to the conventional full-length antibody-coupled ADC Herceptin-MMAE. These combined effects led to Fc-U-ZHER2-MMAE having significantly enhanced tumor treatment ability, as shown in mouse models of NCI-N87 gastric cancer and SK-OV-3 ovarian cancer, where Fc-U-ZHER2-MMAE treatment achieved complete regression of tumors in all or a portion of animals with no obvious side effects and an MTD exceeding 90 mg/kg. These data demonstrate the therapeutic advantages of this cleavable ADC strategy, which could provide a new approach for ADC design.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, Nankai University, Tianjin 300071, China.
ORCID-Profile: Zhangyong Hong
Förderung
- the National Key R&D Program of China
- the National Natural Science Foundation of China
- National Key R&D Program of China
- National Natural Science Foundation of China
Zitieren
APA
Xu, K., Han, J., Yang, L., Cao, L., Li, S., & Hong, Z. (2023). Tumor Site-Specific Cleavage Improves the Antitumor Efficacy of Antibody–Drug Conjugates. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241311011
Vancouver
Xu K, Han J, Yang L, Cao L, Li S, Hong Z. Tumor Site-Specific Cleavage Improves the Antitumor Efficacy of Antibody–Drug Conjugates. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241311011
BibTeX
@article{Xu2023,
author = {Xu, Keyuan and Han, Jiani and Yang, Liu and Cao, Li and Li, Shuang and Hong, Zhangyong},
title = {Tumor Site-Specific Cleavage Improves the Antitumor Efficacy of Antibody–Drug Conjugates},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241311011}
}
EUVIMED